Brief: Aroa Biosurgery Says H1 Product Sales Revenue Was About NZ$17 Mln, Grew 108%
06/10/2021 02:10
Oct 6 (Reuters) - Aroa Biosurgery Ltd ARX.AX :
* H1 FY22 PRODUCT SALES REVENUE OF ABOUT NZ$17 MILLION,
GROWTH OF
108%
* SIGNED A CONTRACT EXTENSION FOR ITS MYRIAD PRODUCTS WITH
HEALTHTRUST
* SEES FY22 PRODUCT SALES REVENUE AT UPPER END OF PREVIOUSLY
ANNOUNCED GUIDANCE OF NZ$30 MILLION TO NZ$33 MILLION
Source text for Eikon: ID:nASX5b2F2g
Further company coverage: ARX.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Aroa Biosurgery
See all newsAustralia-listed Aroa Biosurgery climbs as annual earnings beat guidance
Brief: Aroa Biosurgery Posts Adjusted EBITDA Of NZ$12.6 Million
Aroa Biosurgery climbs as prelim annual results beat outlook
Brief: Aroa Biosurgery Posts FY26 Prelim Total Revenue Of NZ$104 Million
Brief: Aroa Biosurgery Says Expects FY26 Revenue At Upper End Of NZ$92-100 Million